Clinuvel Pharmaceuticals Ltd (ASX: CUV) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Clinuvel Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $896.30 million
P/E Ratio 44.64
Dividend Yield 0.22%
Shares Outstanding 49.41 million
Earnings per share 0.471
Dividend per share 0.04
Year To Date Return -16.94%
Earnings Yield 2.24%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Clinuvel Pharmaceuticals Ltd (ASX: CUV)
    Latest News

    A happy looking woman holding a colourful umbrella against a grey cloudy sky.
    Best Shares

    Top ASX shares to buy in July 2023

    Could these hand-picked shares be the portfolio boosters we need to ring in the new financial year?

    Read more »

    A scientist examining test results.
    Opinions

    Down 35% in a year, is the Imugene share price a buying opportunity right now?

    Is a 35% discount enticing enough to invest in this clinical-stage biotech. Here's my take.

    Read more »

    A young man sits at his desk working on his laptop with a big smile on his face due to his ASX shares going up and in particular the Computershare share price
    Opinions

    10 stocks for 10 years: How I would invest $10,000 in ASX shares right now

    I won't be conned into holding a huge stash of cash. Here are 10 investments I'd rather make for long…

    Read more »

    Businessman at the beach building a wall around his sandcastle, signifying protecting his business.
    Opinions

    3 defensive ASX shares surrounded by wide moats I’d buy with $5,000

    Investors can secure massive returns over the long term if a company holds a sustainable competitive advantage.

    Read more »

    A worried man holds his head and look at his computer.
    Share Fallers

    Why Clinuvel, Cogstate, Omni Bridgeway, and Westgold shares are sinking

    These ASX shares are ending the week in a disappointing fashion...

    Read more »

    Five people are leaping in the shallows of the beach water as sunset shines gold on them.
    52-Week Highs

    5 ASX 200 shares rocketing to new 52-week highs on Tuesday

    These stocks are making the most of the ASX 200's strong start to 2023.

    Read more »

    Arrows pointing upwards with a man pointing his finger at one.
    52-Week Highs

    4 ASX All Ordinaries shares hitting new 52-week highs today

    Do you know the coal and healthcare shares trading at 12-month highs?

    Read more »

    A couple are shocked and elated at the good news they've just seen on their devices.
    Share Gainers

    Why Clinuvel, Nitro, Premier Investments, and Pushpay shares are rising

    These ASX shares are on form on Monday...

    Read more »

    Top ten gold trophy.
    Share Market News

    Here are the top 10 ASX 200 shares today

    These ASX 200 shares posted the biggest gains on Wednesday.

    Read more »

    Man waves goodbye while looking at computer sitting at desk.
    Share Market News

    8 ASX 200 shares got kicked out of the index on Monday. How are they tracking?

    The S&P Dow Jones Indices quarterly rebalance saw eight shares depart the ASX 200 on Monday.

    Read more »

    A woman sits with her hands covering her eyes while lifting her spectacles sitting at a computer on a desk in an office setting.
    Share Gainers

    Why Accent, Bigtincan, Clinuvel, and IVE shares are dropping today

    These ASX shares are in the red today...

    Read more »

    A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
    Share Fallers

    Why Clinuvel, EML, Infomedia, and Link shares are dropping today

    These ASX shares are falling on Monday...

    Read more »

    Frequently Asked Questions

    Yes, Clinuvel Pharmaceuticals has historically paid one unfranked shareholder dividend a year.

    Clinuvel Pharmaceuticals generally pays its shareholder dividend in September.

    Clinuvel Pharmaceuticals does not have a dividend reinvestment plan.

    Clinuvel Pharmaceuticals Limited listed on the ASX on 13 February 2001.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    06 Sep 2022 $0.0400 100.00% Final 21 Sep 2022
    02 Sep 2021 $0.0250 0.00% Final 17 Sep 2021
    03 Sep 2020 $0.0250 0.00% Final 18 Sep 2020
    04 Sep 2019 $0.0250 0.00% Final 19 Sep 2019
    21 Sep 2018 $0.0200 0.00% Final 08 Oct 2018

    CUV ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Clinuvel Pharmaceuticals Ltd

    Clinuvel Pharmaceuticals Ltd (ASX: CUV) is an Australian-based global biopharmaceutical company developing drugs for the treatment of genetic and vascular disorders. Its principal product SCENESSE is a drug for an inherited disorder, erythropoietic protoporphyria, that causes an intolerance to light.

    Its pioneering work aims at preventing the symptoms of skin diseases related to exposure to UV radiation and at repigmentation of the skin due to depigmentation disorders. Geographically, the company derives the majority of its revenue from its US and European markets.

     

    CUV Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    09 Aug 2023 $18.00 $0.00 0.00% 52,586 $17.90 $18.13 $17.70
    08 Aug 2023 $18.00 $0.38 2.16% 50,357 $17.62 $18.00 $17.47
    07 Aug 2023 $17.62 $-0.01 -0.06% 47,381 $17.44 $18.03 $17.44
    04 Aug 2023 $17.63 $0.12 0.69% 56,968 $17.45 $17.92 $17.13
    03 Aug 2023 $17.51 $-0.14 -0.79% 47,110 $17.65 $17.65 $17.20
    02 Aug 2023 $17.65 $-0.59 -3.23% 101,211 $17.98 $17.98 $17.54
    01 Aug 2023 $18.24 $-0.11 -0.60% 25,123 $18.34 $18.35 $18.04
    31 Jul 2023 $18.35 $0.01 0.05% 52,917 $18.40 $18.52 $18.12
    28 Jul 2023 $18.34 $-0.35 -1.87% 22,458 $18.51 $18.72 $18.20
    27 Jul 2023 $18.69 $-0.08 -0.43% 47,957 $18.50 $18.95 $18.34
    26 Jul 2023 $18.77 $0.35 1.90% 97,064 $18.58 $18.97 $18.43
    25 Jul 2023 $18.42 $0.01 0.05% 44,895 $18.36 $18.68 $18.18
    24 Jul 2023 $18.41 $0.35 1.94% 99,332 $18.15 $18.79 $17.94
    21 Jul 2023 $18.06 $-0.34 -1.85% 69,163 $18.30 $18.46 $17.93
    20 Jul 2023 $18.40 $-0.45 -2.39% 109,830 $19.23 $19.35 $18.31
    19 Jul 2023 $18.85 $-0.02 -0.11% 105,911 $19.00 $19.59 $18.16
    18 Jul 2023 $18.87 $1.12 6.31% 118,098 $18.00 $19.05 $18.00
    17 Jul 2023 $17.75 $0.03 0.17% 42,262 $17.62 $17.91 $17.38
    14 Jul 2023 $17.72 $0.01 0.06% 24,886 $17.71 $17.93 $17.51
    13 Jul 2023 $17.71 $0.13 0.74% 21,496 $17.65 $17.84 $17.55
    12 Jul 2023 $17.58 $-0.11 -0.62% 25,272 $17.71 $17.83 $17.37
    11 Jul 2023 $17.69 $0.26 1.49% 21,219 $17.80 $18.00 $17.60

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    26 Jun 2023 Philippe Wolgen Transfer 3 $53,894,748
    Off-market transfer. Assuming off-market transfer of shares
    26 Jun 2023 Philippe Wolgen Buy 1 $27,147
    On-market trade.
    26 Jun 2023 Philippe Wolgen Transfer 3 $53,894,748
    Off-market transfer. Assuming off-market transfer of shares
    04 Nov 2022 Jeffrey Rosenfeld Buy 300 $5,832
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Brenda Mary Shanahan Non-Executive Director Dec 2007
    Mrs Shanahan has more tha 20 year's of experience in medical R&D and commercialisation. She is currently a non executive director of Phoslock Water Solutions Ltd.
    Mrs Susan (Sue) Smith Non-Executive Director Sep 2019
    Mrs Smith is the Chief Executive Officer of the Independent Doctors Federation, a membership organisation representing practicing physicians within the UK independent healthcare sector. Mrs Smith also manages a consultancy business, providing advisory services to a range of healthcare organisations, investors and boards of directors. Prior to her current roles Mrs Smith has a career, serving for 14 years as Chief Executive Officer of The Princess Grace Hospital, London, and 11 years as the Chief Executive Officer of The Portland Hospital for Women and Children, London. Based in London, Mrs Smith is also Non-Executive Board Chair of Women's Health (London West One) Ltd, a specialist medical practice, Non-Executive Director of Elite Medicine Ltd, a precision medicine company, and a Trustee of the HCA International Foundation.
    Dr Philippe J Wolgen Chief Executive OfficerManaging Director Dec 2005
    Dr Wolgen is currently leading the Group's expansion, with an immediate focus on the US and the further development of the product pipeline for various market segments. His focus has been to establish a professional management team to execute the corporate objectives set and prepare next generation of managers.
    Mr Willem A Blijdorp Non-Executive DirectorNon-Executive Chairman Jan 2015
    Mr Blijdorp is an internationally recongnised entrepreneur who has helped build the B&S Group, one of the largest global trading houses, in a period spanning three decades. Willem now serves on its Supervisory Board and is a majority shareholder, focussing on the Group's development and expansion strategy. Mr Blijdorp was recognised for his expertise in merger and acquisitions and commercial leadership as the Ernst & Young Entrepreneur of the Year in the Netherlands, and runner-up in its European Union awards. He is a Chair member of Remuneration and Nomination committee. He is also member of the Audit and Risk Committee.
    Dr Karen Agersborg Non-Executive Director Jan 2018
    Dr Agersborg had previously worked at Reading Hospital, West Reading and at Suburban Hospital, Norristown as Clinical Endocrinologist and served as Chief, Endocrinology, Diabetes, Metabolism at Chestnut Hill Hospital. Dr Agersborg had a career in managing commercial sales & distribution at Wyeth Pharmaceuticals (formerly Ayerst Laboratories). Dr Agersborg is also integral to setting US commercial strategy, pending US approval of SCENESSE, a decision on an approval expected later in 2019.
    Dr Jeffrey Rosenfeld Non-Executive Director Nov 2019
    Dr Rosenfeld has experience in senior healthcare and research executive roles and career in the Australian Army Reserve. He was the Founding Director of Monash University Institute of Medical Engineering (MIME-Melbourne) and acted as Board Chair for the Security and Health Executive Leadership Institute at The University of Melbourne. For 15 years Dr Rosenfeld was Director of Neurosurgery at the Alfred Hospital, concurrently holding for nine years the position of Professor and Head of the Department of Surgery at Monash University. Dr Rosenfeld is an active member of the Melbourne community and is involved in various charitable causes. He has devoted much of his time to the Australian-Aid funded Pacific Islands Project for transfer of clinical skills and knowhow to healthcare professionals in Papua New Guinea, Fiji and the Solomon Islands. One of Australia's senior and experienced military surgeons, Dr Rosenfeld served on eight deployments to Rwanda, Bougainville, East Timor, the Solomon Islands and Iraq. Having attained the rank of Major General, Dr Rosenfeld is also a former Surgeon General of the Australian Defence Force and remains active in defence and veterans' affairs organisations.In 2018, he received the International Lifetime Recognition Award of the American Association of Neurological Surgeons.
    Sir Andrew Likierman Non-Executive Director Apr 2022
    Sir Likierman has experience between public, private and academic positions. He is Professor of Management Practice at the London Business School and was its Dean from 2009 to 2017. He is currently working on the role of judgement in management, with his work used by many organisations. In the private sector, he served as non-executive Director of Times Newspaper Holdings Ltd, Monument Bank, Barclays Bank plc, quoted insurance Lloyds underwriter Beazley plc, Applied Intellectual Capital plc, and market research firm MORI Ltd. Among many roles in the public sector, he worked in the UK Cabinet Office, and spent 11 years as Head of the UK Government Financial Management Service, during five of which he was also the Chief Financial Officer of the UK Treasury (Finance Ministry). He was knighted for public service in 2001. He has also served as non-executive Director at the Bank of England, non-executive Chair of the (UK) National Audit Office and non-executive Director and Vice-Chairman of the Tavistock and Portman NHS Trust.
    Mr Darren Keamy Chief Finance OfficerCompany Secretary Dec 2005
    -
    Darren Keamy Chief Finance OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 11,368,759 30.24%
    Bnp Paribas Nominees Pty Ltd Acf Clearstream 5,942,326 6.31%
    BNP Paribas Nominees Pty Ltd Six Sis Ltd (Drp A/C) 5,130,894 5.99%
    J P Morgan Nominees Australia Pty Limited 3,819,117 5.68%
    Acn 108 768 896 Pty Ltd 2,780,040 4.08%
    Ender 1 Llc 2,590,824 3.89%
    Citicorp Nominees Pty Limited 2,385,285 2.79%
    Dr Philippe Jacques Wolgen 975,511 2.35%
    BNP Paribas Nominees Pty Ltd (Ib Au Noms Retail Client Drp) 856,796 1.79%
    M Badcock And P Chu Superannuation Fund Pty Ltd 632,947 1.75%
    National Nominees Limited (Db A/C) 603,990 1.75%
    Dr Mark Edwin Badcock 547,563 1.60%
    BNP Paribas Noms Pty Ltd (Drp) 452,391 1.58%
    BNP Paribas Nominees Pty Ltd (Agency Lending Drp A/C) 271,419 1.17%
    BNP Paribas Noms (Nz) Ltd (Drp) 241,539 1.14%
    Merrill Lynch (Australia) Nominees Pty Limited 238,237 0.98%
    Mr David William Trevorrow 222,222 0.87%
    Truebell Capital Pty Ltd (Trubell Investment Fund) 200,000 0.82%
    HSBC Custody Nominees (Australia) Limited A/C 2 192,758 0.82%
    Mr David John Lewis 187,000 0.80%

    Profile

    since

    Note